Opportunistic infections in HIV: Difference between revisions
From IDWiki
(→) |
No edit summary |
||
| (5 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
{| class="wikitable" |
{| class="wikitable" |
||
! |
!CD4 |
||
! |
!Infections |
||
! |
!Action |
||
|- |
|- |
||
| |
|Any |
||
| |
|[[Tuberculosis]] |
||
| |
|Screen for [[latent tuberculosis]]<br />Vaccinate for [[pneumococcus]], [[influenza]], [[varicella]], [[HPV]] (if appropriate), [[hepatitis A]], and [[hepatitis B]] |
||
|- |
|- |
||
| |
|<500 |
||
| |
|[[Kaposi sarcoma]] (HHV-8)<br />[[Herpes simplex]]<br />[[Varicella-zoster]] |
||
| |
| |
||
|- |
|- |
||
| |
|<300 |
||
| |
|[[Candida]]<br />[[Molluscum contagiosum]]<br />Diarrhea from [[microsporidia]] and [[cryptosporidia]] |
||
| |
| |
||
|- |
|- |
||
| |
|<200 |
||
| |
|''[[Pneumocystis jirovecii]]'' pneumonia |
||
| |
|Start [[PJP]] prophylaxis ([[TMP-SMX]] SS or DS) |
||
|- |
|- |
||
| |
|<150 |
||
| |
|[[Dimorphic fungi]] |
||
| |
|Start [[histoplasmosis]] prophylaxis if high risk (occupation or hyperendemic) ([[itraconazole]]) |
||
|- |
|- |
||
| |
|<100 |
||
| |
|[[Toxoplasmosis]]<br />[[Cryptococcus]] |
||
| |
|Start [[toxoplasmosis]] prophylaxis if IgG positive ([[TMP-SMX]] DS) |
||
|- |
|- |
||
| |
|<50 |
||
| |
|[[Mycobacterium avium complex]]<br />[[Cytomegalovirus]], including retinitis<br />Progressive multifocal leukoencephalopathy (PML) from [[JC virus]] |
||
| |
|Start [[Mycobacterium avium complex|MAC]] prophylaxis ([[azithromycin]]) |
||
|} |
|} |
||
== |
==Prophylaxis regimens== |
||
{| class="wikitable" |
{| class="wikitable" |
||
! |
!Infection!!Preferred!!Alternative |
||
|- |
|- |
||
| rowspan=4 | |
| rowspan="4" |''[[Pneumocystis jirovecii]]''<br />(CD4 <200 or <14%) |
||
| rowspan=4 | |
| rowspan="4" |[[TMP-SMX]] 1 DS or SS PO daily |
||
| |
|[[TMP-SMX]] 1 DS PO three times weekly |
||
|- |
|- |
||
| |
|[[Dapsone]] 100 mg PO daily or 50 mg PO BID |
||
|- |
|- |
||
| |
|[[Pentamidine]] nebs 300 mg every month |
||
|- |
|- |
||
| |
|[[Atovaquone]] 1500 mg PO daily |
||
|- |
|- |
||
| rowspan=4 | |
| rowspan="4" |''[[Toxoplasma gondii]]''<br />(CD4 <100 and IgG positive) |
||
| rowspan=4 | |
| rowspan="4" |[[TMP-SMX]] 1 DS PO daily |
||
| |
|[[TMP-SMX]] 1 DS PO three times weekly |
||
|- |
|- |
||
| |
|[[TMP-SMX]] 1 SS PO daily |
||
|- |
|- |
||
| |
|[[Dapsone]] 50 mg PO daily + pyrimethamine/leucovorin PO weekly |
||
|- |
|- |
||
| |
|[[Atovaquone]] 1500 mg PO daily |
||
|- |
|- |
||
| rowspan=3 | |
| rowspan="3" |''[[Mycobacterium avium complex]]''<br />(CD4 <50 and ''not'' on HIV therapy) |
||
| rowspan=3 | |
| rowspan="3" |[[Azithromycin]] 1200 mg PO once weekly |
||
| |
|[[Clarithromycin]] 500 mg PO BID |
||
|- |
|- |
||
| |
|[[Azithromycin]] 600 mg PO twice weekly |
||
|- |
|- |
||
| |
|[[Rifabutin]], dose-adjusted to HIV meds |
||
|- |
|- |
||
| |
|''[[Histoplasma capsulatum]]''<br />(CD4 <150 and high risk) |
||
| |
|[[Itraconazole]] 200 mg PO once daily |
||
| |
| |
||
|- |
|||
|''[[Coccidioides immitis]]''<br />(new IgM or IgG positivity in an endemic area and with CD4 <250) |
|||
|[[Fluconazole]] 400 mg PO daily |
|||
| |
|||
|} |
|} |
||
"High risk" for ''Histoplasma'' includes occupational exposure or residence in a community with a hyperendemic rate of histoplasmosis (>10 cases/100 patient-years) |
* "High risk" for ''Histoplasma'' includes occupational exposure or residence in a community with a hyperendemic rate of histoplasmosis (>10 cases/100 patient-years) |
||
== |
==Further Reading== |
||
* |
*[https://aidsinfo.nih.gov/guidelines/html/4/adult-and-adolescent-opportunistic-infection/0 AIDSinfo Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents] |
||
[[Category:HIV]] |
[[Category:HIV]] |
||
Latest revision as of 13:22, 22 October 2020
| CD4 | Infections | Action |
|---|---|---|
| Any | Tuberculosis | Screen for latent tuberculosis Vaccinate for pneumococcus, influenza, varicella, HPV (if appropriate), hepatitis A, and hepatitis B |
| <500 | Kaposi sarcoma (HHV-8) Herpes simplex Varicella-zoster |
|
| <300 | Candida Molluscum contagiosum Diarrhea from microsporidia and cryptosporidia |
|
| <200 | Pneumocystis jirovecii pneumonia | Start PJP prophylaxis (TMP-SMX SS or DS) |
| <150 | Dimorphic fungi | Start histoplasmosis prophylaxis if high risk (occupation or hyperendemic) (itraconazole) |
| <100 | Toxoplasmosis Cryptococcus |
Start toxoplasmosis prophylaxis if IgG positive (TMP-SMX DS) |
| <50 | Mycobacterium avium complex Cytomegalovirus, including retinitis Progressive multifocal leukoencephalopathy (PML) from JC virus |
Start MAC prophylaxis (azithromycin) |
Prophylaxis regimens
| Infection | Preferred | Alternative |
|---|---|---|
| Pneumocystis jirovecii (CD4 <200 or <14%) |
TMP-SMX 1 DS or SS PO daily | TMP-SMX 1 DS PO three times weekly |
| Dapsone 100 mg PO daily or 50 mg PO BID | ||
| Pentamidine nebs 300 mg every month | ||
| Atovaquone 1500 mg PO daily | ||
| Toxoplasma gondii (CD4 <100 and IgG positive) |
TMP-SMX 1 DS PO daily | TMP-SMX 1 DS PO three times weekly |
| TMP-SMX 1 SS PO daily | ||
| Dapsone 50 mg PO daily + pyrimethamine/leucovorin PO weekly | ||
| Atovaquone 1500 mg PO daily | ||
| Mycobacterium avium complex (CD4 <50 and not on HIV therapy) |
Azithromycin 1200 mg PO once weekly | Clarithromycin 500 mg PO BID |
| Azithromycin 600 mg PO twice weekly | ||
| Rifabutin, dose-adjusted to HIV meds | ||
| Histoplasma capsulatum (CD4 <150 and high risk) |
Itraconazole 200 mg PO once daily | |
| Coccidioides immitis (new IgM or IgG positivity in an endemic area and with CD4 <250) |
Fluconazole 400 mg PO daily |
- "High risk" for Histoplasma includes occupational exposure or residence in a community with a hyperendemic rate of histoplasmosis (>10 cases/100 patient-years)
